Group 1 - The strategic acquisition of shares in MicroPort Medical by the Shanghai Biomedical M&A Fund signifies the fund's role in empowering local biopharmaceutical "chain leader" enterprises for stable development and value reconstruction [1][2] - MicroPort Medical is recognized as a leading innovative high-end medical device company in China, playing a crucial role in the global high-end medical device industry chain [1][3] - The transaction aims to provide critical support to domestic "chain leader" enterprises, ensuring the stability and development of their core assets [1][2] Group 2 - The M&A Fund will leverage its state-owned background and industry resources to support MicroPort Medical's core business expansion and potential strategic acquisitions [1][2] - MicroPort Medical has successfully nurtured multiple listed companies and specialized enterprises, forming a unique "MicroPort system" ecosystem [2] - The involvement of the M&A Fund is expected to enhance the competitive advantage of MicroPort Medical and strengthen the overall industrial ecosystem [2] Group 3 - MicroPort Medical, established in 1998, has expanded its business into various fields, including cardiovascular intervention, orthopedics, and surgical robots, with operations in over 20,000 hospitals across 100 countries by the end of 2024 [3] - The company has cultivated six publicly listed companies and numerous specialized enterprises, representing a significant force in Shanghai's technological innovation and industrial transformation [3] Group 4 - Shanghai Shihua Capital, as an active fund management platform under the Shihua Group, focuses on investment opportunities in strategic emerging industries such as biopharmaceuticals and green environmental protection [4] - The fund aims to support national strategies and the construction of biopharmaceutical hubs through a multi-currency and multi-stage fund matrix [4]
上海生物医药并购基金战略入股微创医疗